Clinical Trials Logo

Carcinoma, Renal Cell clinical trials

View clinical trials related to Carcinoma, Renal Cell.

Filter by:

NCT ID: NCT00561912 Terminated - Clinical trials for Renal Cell Carcinoma

Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma

Start date: October 2007
Phase: Phase 2
Study type: Interventional

Primary Objective: - To determine the progression-free survival (PFS) times for patients with advanced renal cell carcinoma (RCC) treated with decitabine and interferon alfa-2b. Secondary Objectives: - To determine the toxicity of the combination of decitabine and interferon alfa-2b at the proposed dose and schedule in patients with advanced RCC - To determine overall response by Response Evaluation Criteria in Solid Tumors (RECIST) criteria for patients with advanced RCC treated with decitabine and interferon alfa-2b. - To determine the overall survival times for patients with advanced RCC treated with decitabine and interferon. - To study the effects of decitabine and interferon alfa-2b on DNA methylation and gene expression in patients' tumor and non-tumor tissues and their correlation with clinical outcomes. - To characterize the modulation of cellular immunity induced by the combination of decitabine and interferon alfa-2b in patients with advanced RCC and to correlate these results with clinical outcomes.

NCT ID: NCT00557830 Terminated - Clinical trials for Renal Cell Carcinoma

Randomized Study of Sorafenib Dose Escalation in Patients With Previously Untreated Metastatic Renal Cell Carcinoma

Start date: January 2008
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to compare the effectiveness of a dose-escalation regimen (400 to 800mg bid) relative to the standard dosing regimen (400mg bid) of sorafenib given in patients with metastatic RCC. The secondary objectives are to evaluate the effects of the dose-escalation regimen on the quality of life (QoL) of patients with metastatic RCC and to characterize the safety and tolerability profile of a dose-escalation regimen of sorafenib in patients with metastatic RCC.

NCT ID: NCT00540969 Terminated - Pain Clinical Trials

Cryoablation or External-Beam Radiation Therapy in Treating Patients With Painful Bone Metastases

Start date: February 2008
Phase: Phase 3
Study type: Interventional

RATIONALE: Cryoablation kills cancer cells by freezing them. Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells. It is not yet known whether cryoablation is more effective than external-beam radiation therapy in treating painful bone metastases. PURPOSE: This randomized phase III clinical trial is studying cryoablation to see how well it works compared with external-beam radiation therapy in treating patients with painful bone metastases.

NCT ID: NCT00523640 Terminated - Clinical trials for Carcinoma, Renal Cell

A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Cell Carcinoma

Start date: March 2005
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find out what effects (good and bad) the combination of the chemotherapy drugs gemcitabine, capecitabine, and bevacizumab has on a patient and kidney cancer.

NCT ID: NCT00522249 Terminated - Clinical trials for Carcinoma, Renal Cell

Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC

Start date: May 2007
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the combination of Pegylated Alfa Interferon (PEG-Intron), Sunitinib and Tarceva to see if this drug combination delays the disease progression of patients with metastatic Renal Cell Carcinoma. The first phase of this study will determine the best dose of Peg-Intron, Sunitinib and Tarceva when given in combination. The safety of giving these drugs in combination and response to treatment will also be examined.

NCT ID: NCT00520533 Terminated - Clinical trials for Renal Cell Carcinoma (RCC)

Study of Safety and Functional Imaging of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma

Start date: February 2008
Phase: Phase 1
Study type: Interventional

This clinical trial explores the safety, efficacy, and effects on functional imaging of cG250 monoclonal antibody (mAb) administered intravenously weekly in combination with daily oral sunitinib, in patients with advanced renal cell carcinoma.

NCT ID: NCT00496756 Terminated - Kidney Cancer Clinical Trials

Sorafenib in Treating Patients With Metastatic or Unresectable Kidney Cancer

Start date: March 1, 2007
Phase: Phase 2
Study type: Interventional

RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying the side effects and how well sorafenib works in treating patients with metastatic or unresectable kidney cancer.

NCT ID: NCT00492440 Terminated - Kidney Cancer Clinical Trials

Interleukin-7 in Treating Patients With Metastatic Melanoma or Locally Advanced or Metastatic Kidney Cancer

Start date: May 2007
Phase: Phase 1
Study type: Interventional

RATIONALE: Interleukin-7 may stimulate the white blood cells to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of interleukin-7 in treating patients with metastatic melanoma or locally advanced or metastatic kidney cancer.

NCT ID: NCT00491738 Terminated - Clinical trials for Renal Cell Carcinoma

A Study Evaluating the Efficacy and Safety of Sunitinib With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer (SABRE-R)

Start date: August 2007
Phase: Phase 2
Study type: Interventional

This is a Phase II, multicenter, randomized, blinded, placebo-controlled study designed to evaluate the safety and efficacy of combining bevacizumab with sunitinib relative to placebo with sunitinib in patients with metastatic RCC who have not received prior systemic therapy for metastatic disease. The study will enroll approximately 100 patients at approximately 20 centers in the United States.

NCT ID: NCT00491075 Terminated - Clinical trials for Renal Cell Carcinoma

Pemetrexed Plus Gemcitabine in Renal Cell Cancer

Start date: December 2005
Phase: Phase 2
Study type: Interventional

Primary Objective: - To determine the clinical activity of Pemetrexed + Gemcitabine in non-clear cell renal cell cancer (RCC). Clinical activity will take into account response rate and progression free survival (PFS). Secondary Objectives: - To determine the toxicity of Pemetrexed + Gemcitabine in non-clear cell RCC. - To estimate the survival rate of patients with non-clear cell RCC treated with this combination.